目的 研究血脂異?；颊咻d脂蛋白（ApoE）、有機(jī)陰離子轉(zhuǎn)運(yùn)蛋白家族成員1B1（SLCO1B1）基因多態(tài)性與阿托伐他汀調(diào)脂治療后血脂、肝功能的相關(guān)性。方法 選取2020年1月—2023年9月就診于滄州市人民醫(yī)院的128例高脂血癥患者，阿托伐他汀治療至少4周，檢測(cè)ApoE、SLCO1B1基因和血脂、肝功能指標(biāo)，分析其因型與調(diào)脂療效、肝功能指標(biāo)關(guān)系。結(jié)果 阿托伐他汀治療后，ApoE基因表型E2組三酰甘油（TG）、高密度脂蛋白膽固醇（HDL-C）水平均較治療前改善，E3組總膽固醇（TC）、HDL-C、低密度脂蛋白膽固醇（LDL-C）水平均較治療前改善，E4組HDL-C水平均較治療前改善，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，ApoE基因表型各組丙氨酸轉(zhuǎn)氨酶（ALT）差異無(wú)統(tǒng)計(jì)學(xué)意義，僅E3組谷氨酰轉(zhuǎn)移酶（GGT）差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。阿托伐他汀治療后，SLCO1B1基因表型I型的TC、TG、HDL-C、LDL-C均較治療前改善，Ⅱ型HDL-C較治療前改善，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，SLCO1B1基因表型各組ALT、GGT差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 臨床使用阿托伐他汀時(shí)，可檢測(cè)ApoE、SLCO1B1基因多態(tài)性評(píng)估降脂療效，實(shí)現(xiàn)阿托伐他汀個(gè)體化用藥。

Objective To investigate the association of ApoE and SLCO1B1 polymorphism with lipid and liver function in patients with dyslipidemia after lipid-lowering with atorvastatin.Methods A total of 128 patients with dyslipidemia in Cangzhou People's Hospital from January 2020 to September 2023 were collected. The patient received at least 4 weeks of atorvastatin therapy. ApoE genes, SLCO1B1 genes, blood lipids, and liver function indicators were detected. The relationship between their genotype and lipid-lowering efficacy, as well as liver function indicators was evaluate. Results After atorvastatin treatment, the levels of TG and HDL-C of ApoE gene phenotype in E2 group, the levels of TC, HDL-C, LDL-C, and LDL-C in E3 group, and the levels of HDL-C in E4 group were improved compared with before treatment, and the difference was statistically significant (P < 0.05). After treatment, there was no statistically significant difference in ALT among ApoE gene phenotype groups, while only the difference in GGT of E3 group was statistically significant (P < 0.05). After atorvastatin therapy, TC, TG, HDL-C, and LDL-C of SLCO1B1 gene phenotype I improved compared to before treatment, while HDL-C of SLCO1B1 gene phenotype II improved compared to before treatment, with statistical significance (P < 0.05). After treatment, there was no statistically significant difference in ALT and GGT among the SLCO1B1 gene phenotype groups. Conclusion In the clinical application of statins, the lipid-lowering efficacy can be evaluated by detecting APOE and SLCO1B1 gene polymorphisms, and the individualized use of atorvastatin can be realized.

R972

河北省醫(yī)學(xué)科學(xué)研究課題（20220310）